<DOC>
	<DOCNO>NCT01646424</DOCNO>
	<brief_summary>The aim study describe patient preference budesonide/formoterol fix dose combination treatment COPD , find factor strongly associate well attitude medication .</brief_summary>
	<brief_title>Validation Questionnaire Assessment Patient Satisfaction Budesonide/Formoterol Fix Combination Dry Powder Inhalers ( DPI ) Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>Validation questionnaire assessment patient satisfaction budesonide/formoterol fix combination DPI COPD</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Provision subject inform consent outpatient Clinical diagnosis COPD accord ICD10 classification , female male , age â‰¥ 40 year To prescribe fix dose combination inhale budesonide/formoterol fix combination least 3 month study start Pregnancy woman Use inhaled medication via meter dose inhaler ( pMDI ) Currently participate randomize clinical trial include study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>COPD ,</keyword>
	<keyword>Patient satisfaction ,</keyword>
	<keyword>fix combination ,</keyword>
	<keyword>NIS Turkey ,</keyword>
	<keyword>turbuhaler ,</keyword>
	<keyword>FSI-10</keyword>
</DOC>